Incannex Healthcare Inc. (IXHL): Total Assets
$72.98M
As of 2026-06-30
$70.39M
As of 2026-09-30
+45.3%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $72.98M | +256.9% | 2026-09-25, Balance as of period end |
| 2025-06-30 | $20.45M | +19.9% | 2026-09-25, Balance as of period end |
| 2024-06-30 | $17.05M | -28.3% | 2025-09-29, Balance as of period end |
| 2023-06-30 | $23.78M | n/a | 2024-09-30, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | 2026-06-30 | $72.98M | +256.9% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare IXHL, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗